Citations

Showing 10 of 108152 citations.

Prediction of Exercise Capacity and Training Prescription from the 6-Minute Walk Test and Rating of Perceived Exertion
Porcari, John P. , Foster, Carl , Cress, Maria L., Larson, Rachel, Lewis, Hannah B , Cortis, Cristina , Doberstein, Scott, Donahue, Marc, Fusco, Andrea , Radtke, Kimberly, Lewis, Hannah

Mayo Clinic

Journal of Functional Morphology and Kinesiology | June 14, 2021 | Volume: 6 | Issue: 2 | Pages: 52

10.3390/jfmk6020052 | PMID 34198628 Get It

Walking tests, such as the 6-min walk test (6MWT), are popular methods of estimating peak oxygen uptake (VO2peak) in clinical populations. However, the strength of the distance vs. VO2peak relationship is not strong, and there are no equations for estimating ventilatory threshold (VT), which is important for training prescription and prognosis. Since the 6MWT is often limited by walking mechanics, prediction equations that include simple additional predictors, such as the terminal rating of perceived exertion (RPE), hold the potential for improving the prediction of VO2max and VT. Therefore, this study was designed to develop equations for predicting VO2peak and VT from performance during the 6MWT, on the basis of walking performance and terminal RPE. Clinically stable patients in a cardiac rehabilitation program (N = 63) performed the 6MWT according to the American Thoracic Society guidelines. At the end of each walk, the subject provided their terminal RPE on a 6–20 Borg scale. Each patient also performed a maximal incremental treadmill test with respiratory gas exchange to measure VO2peak and VT. There was a good correlation between VO2peak and 6MWT distance (r = 0.80) which was improved by adding the terminal RPE in a multiple regression formula (6MWT + RPE, R2 = 0.71, standard error of estimate, SEE = 1.3 Metabolic Equivalents (METs). The VT was also well correlated with walking performance, 6MWT distance (r = 0.80), and was improved by the addition of terminal RPE (6MWT + RPE, R2 = 0.69, SEE = 0.95 METs). The addition of terminal RPE to 6MWT distance improved the prediction of maximal METs and METs at VT, which may have practical applications for exercise prescription.
Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials
Sutiwisesak, Rujapope , Rodriguez, Moses , Warrington, Arthur E. , Rodriguez, Moses , Burns, Terry C.

Mayo Clinic

Expert Opinion on Investigational Drugs | June 14, 2021 | Volume: 30 | Issue: 8 | Pages: 857-876

10.1080/13543784.2021.1942840 | PMID 34126015 Get It

Diagnosis and Treatment of Femoral Head Osteonecrosis: A Protocol for Development of Evidence-Based Clinical Practice Guidelines
Cui, Quanjun , Baek, Seung‐Hoon , Drescher, Wolf , Hernigou, Philippe , Jones, Lynne C. , Koo, Kyung‐Hoi , Lee, Mel, Mont, Michael A. , Reichert, Ines , Salem, Hytham S. , Stronach, Ben M., Sugano, Nobuhiko , Zhao, Dewei , Cheng, Edward Y. , Goodman, Stuart B. , Ando, Wataru , Bakker, Caitlin , Kim, Harry K.W. , Kim, Shin‐Yoon , Kim, Tae-Young , Ha, Yong‐Chan , Sakai, Takashi , Sierra, Rafael J. , Yamamoto, Takuaki , Yoon, Byung‐Ho

Mayo Clinic

Surgical Technology Online | June 14, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.52198/21.sti.38.os1437 | PMID 34043232 Get It

Introduction: There are many treatment options for patients who have osteonecrosis of the femoral head (ONFH) and management strategies vary widely both among and within individual countries. Although many researchers have attempted to elucidate the optimal strategies for managing this disease, the lack of large-scale randomized control trials and the lack of agreement on disease staging have curtailed the development of clear-cut guidelines. Materials and Methods: The Association Research Circulation Osseous (ARCO) group sought to address three questions for the management of patients who have ONFH: 1) What imaging studies are most sensitive and specific for the diagnostic evaluation of patients who have ONFH?; 2) What is the best treatment strategy for preventing disease progression in patients who have pre-collapse lesions?; and 3) What is the best treatment strategy for patients who have post-collapse disease? The Patient, Intervention, Comparison, and Outcome (PICO) format was used to formulate the search strategy for each research question. A systematic review will be performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. ARCO participants have been allocated to three groups, each representing one of the PICO questions. After qualitative and quantitative analysis of the data extracted from studies pertaining to each of the three research questions, a set of evidence-based clinical practice guidelines will be proposed for the management of patients who have ONFH. Discussion: It is not always clear which treatment method is optimal for the management of ONFH. Thus, many surgeons have developed and performed various procedures based on patient-specific factors. As there is no consensus on the optimal treatment for various stages of disease, it was clear that developing evidence-based clinical practice guidelines would provide more structure and uniformity to management of these patients. Therefore, the results of this systematic review will lead to the development guidelines that may improve patient-care strategies and result in better outcomes for patients who have ONFH.
Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies
Xie, Zhuoer , Saliba, Antoine N. , Abeykoon, Jithma P. , Almquist, Daniel , Wiedmeier, Julia E. , Andrade-Gonzalez, Xavier , Hickman, Ashley , Sorenson, K, Rakshit, Sagar, Wee, Christopher Eing , Tella, Sri Harsha , Kommalapati, Anuhya , Abdallah, Nadine , Pritchett, Joshua C. , Uprety, Dipesh , Badley, Andrew D. , Bryce, Alan H. , Gangat, Naseema , Thompson, Carrie A. , Leventakos, Konstantinos , Saliba, Antoine N. , Almquist, Daniel R , Wiedmeier-Nutor, Julia E , Andrade-Gonzalez, Xavier , Hickman, Ashley , Sorenson, Karl, Wee, Christopher , Kommalapati, Anuhya , Pritchett, Joshua , Uprety, Dipesh , Badley, Andrew, Manochakian, Rami , Ailawadhi, Sikander , Bryce, Alan H , Hubbard, Joleen , Thompson, Carrie A , Witzig, T.E. , McWilliams, Robert R , Badley, Andrew D , Xie, Zhuoer , Saliba, Antoine N , Saliba, Antoine N , Majeed, Umair , Bezerra, Evandro D. , Andrade, Mariza de , Manochakian, Rami , Ailawadhi, Sikander , Hubbard, Joleen M. , Witzig, Thomas E. , McWilliams, Robert R. , Hálfdánarson, Þorvarður R.

Mayo Clinic

JCO Oncology Practice | June 14, 2021 | Volume: 17 | Issue: 9 | Pages: e1382-e1393

10.1200/op.21.00177 | PMID 34125579 Get It

PURPOSE: The benefit of routine pre-emptive screening for severe acute respiratory syndrome coronavirus 2 infections in patients with cancer before cancer-directed therapies is unclear. Herein, we characterize the outcomes of a cohort of patients with cancer who were diagnosed with COVID-19 by routine screening (RS) in comparison with those diagnosed on the basis of clinical suspicion or exposure history (nonroutine screening [NRS]). METHODS: A multisite prospective observational study was conducted at three major and five satellite campuses of the Mayo Clinic Cancer Center between March 18 and July 31, 2020. The primary outcome was COVID-19–related hospital admission. Secondary outcomes included intensive care unit admissions and all-cause mortality. RESULTS: Five thousand four hundred fifty-two patients underwent RS in the outpatient setting only, and 44 (0.81%) were diagnosed with COVID-19. RS detected 19 additional patients from the scheduled inpatient admissions for surgical or interventional procedures or inpatient chemotherapy. One hundred sixty-one patients were diagnosed with COVID-19 on the basis of NRS. COVID-19–related hospitalization rate (17.5% v 26.7%; P = .14), intensive care unit admission (1.6% v 5.6%; P = .19), and mortality (4.8% v 3.7%; P = .72) were not significantly different between the RS and NRS groups. In the multivariable analysis, age ≥ 60 years (odds ratio, 4.4; P = .023) and an absolute lymphocyte count ≤ 1.4 × 109/L (odds ratio, 9.2; P = .002) were independent predictors of COVID-19–related hospital admission. CONCLUSION: The COVID-19 positivity rate was low on the basis of RS. Comparing the hospital admission and mortality outcomes with the NRS cohort, there were no significant differences. The value of routine pre-emptive screening of asymptomatic patients with cancer for COVID-19 remains low.
Randomized, Double-Blind Trial on the Impact of Word Count in Cancer Clinical Trial Consent Forms
Almodallal, Yahya , Duong, Quyen, Satele, Daniel , Novotny, Paul J. , Cook, Kathryn , Chauhan, Cynthia, Daiss, Michelle K., Le‐Rademacher, Jennifer , Looker, Sherry, Martin, Nichole , Smestad, Michanda F., Mandrekar, Sumithra J. , Jatoi, Aminah , Novotny, Paul, Cook, Kathryn D , Mandrekar, Sumithra J , Jatoi, Aminah , Le-Rademacher, Jennifer G , Winham, Stacey J.

Mayo Clinic

JCO Oncology Practice | June 14, 2021 | Volume: 17 | Issue: 10 | Pages: e1460-e1472

10.1200/op.21.00071 | PMID 34125586 Get It

PURPOSE:This randomized, double-blind study sought to understand whether cancer clinical trial consent form verbosity detracts from patients' decision making on trial enrollment.METHODS:This trial tested mock consent forms of 2,000, 4,000, and 6,000 words. The first two comprised the two experimental arms and the third the control arm. Phase II was conducted to identify the promising arm, which, in phase III, was compared with the control arm. Each consent form described the same trial. Eligible adult patients reported a cancer history and English literacy. The primary end point used a patient-reported Likert scale to assess the relationship between information in the consent form and trial decision making.RESULTS:In phase II, 93 patients were accrued and prompted the selection of the 2,000-word consent form for phase III. In phase III, 182 patients were recruited, resulting in 240 total evaluable patients to compare the 2,000-word versus the 6,000-word arm (control). For the primary end point, 103 (84%) and 107 (91%) patients in the 2,000- and 6,000-word arms, respectively, strongly agreed or agreed with the following: “The information in this consent form helped me make a decision about whether or not to enroll in the trial” (two-sided, P = .14). Median time to read each consent form was 8 and 12 minutes, respectively (two-sided, P < .0001). Among those assigned these consent forms, 84% and 73%, respectively (two-sided, P = .04) signed or expressed a willingness to sign.CONCLUSION:This study's primary end point was not met. However, secondary outcomes suggest a need to further study the efficiency and efficacy of shorter consent forms for cancer clinical trial enrollment.
Establishing a core outcome measure for pain in patients with autosomal dominant polycystic kidney disease: a consensus workshop report
Natale, Patrizia , Harris, Tess , Hannan, Elyssa, Ju, Angela, Burnette, Eva, Casteleijn, Niek F. , Chapman, Arlene B., Eastty, Sarah, Gansevoort, Ron T. , Hogan, Marie C. , Horie, Shigeo , Knebelmann, Bertrand , Sandford, Richard, Craig, Jonathan C. , Rangan, Gopala K. , Viecelli, Andrea K. , Evangelidis, Nicole , Guha, Chandana , Logeman, Charlotte , Manera, Karine , González, Andrea Matus , Howell, Martin , Hogan, Marie, Amir, Noa , Manera, Karine , Howell, Martin , Hogan, Marie C , Perrone, Ronald D. , Tong, Allison , Lee, Richard , Mustafa, Reem A , Baumgart, Amanda , Sautenet, Bénédicte , Strippoli, Giovanni FM , Cho, Yeoungjee

Mayo Clinic

Clinical Kidney Journal | June 14, 2021 | Volume: 15 | Issue: 3 | Pages: 407-416

10.1093/ckj/sfab110 | PMID 35211300 Get It

Abstract Background Pain is the highest prioritized patient-reported outcome in people with autosomal dominant polycystic kidney disease (ADPKD) but remains infrequently and inconsistently measured in clinical trials and poorly managed in clinical settings. A recently completed systematic review of pain in ADPKD identified 26 different outcome measures. None of these measures were considered appropriate as a core outcome measure due to the lack of patient-important dimensions, inadequate content, relatively long duration of completion time and limited evidence to support psychometric robustness. Methods We convened an international Standardized Outcomes in Nephrology–Polycystic Kidney Disease consensus workshop involving 21 patients/caregivers and 40 health professionals (clinicians, nurses, researchers, policy makers and industry representatives) from 18 countries to discuss the identification or development of a core outcome measure for pain. Results Four themes were identified highlighting fundamental issues for the measurement of pain in ADPKD: distressing and disrupting life participation; variability and ambiguity in defining pain; stigma, frustration and adaptation to pain; and ensuring validity and feasibility of pain measures. Conclusions Existing measures were found to be insufficient in capturing pain as a core outcome and there was consensus on the need for a new validated measure that is simple, succinct and addresses the impact of pain on life participation. This measure will facilitate the appropriate prioritization of pain in all trials and guide clinical decision making in people with ADPKD.
The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing (June 2021)
Hanson, Kimberly E. , Altayar, Osama , Caliendo, Angela M. , Arias, Cesar Andres Diaz , Hayden, Mary K. , Lee, Mark J. , Loeb, Mark , Alayli, Abdallah El , Sultan, Shahnaz , Falck–Ytter, Yngve , Lavergne, Valéry , Mansour, Razan , Patel, Payal , Bhimraj, Adarsh , Hanson, Kimberly , Altayar, Osama , Englund, Janet A. , Patel, Robin , Morgan, Rebecca L. , Murad, M. Hassan , Mustafa, Reem A

Mayo Clinic

Clinical Infectious Diseases | June 14, 2021 | Volume: 78 | Issue: 7 | Pages: e208-e229

10.1093/cid/ciab557 | PMID 34160592 Get It

Abstract Immunoassays designed to detect SARS-CoV-2 protein antigens are now commercially available. The most widely used tests are rapid lateral flow assays that generate results in ~15 minutes for diagnosis at the point-of-care. Higher throughput, laboratory-based SARS-CoV-2 antigen (Ag) assays have also been developed. The overall accuracy of SARS-CoV-2 Ag tests, however, is not well defined. The Infectious Diseases Society of America (IDSA) convened an expert panel to perform a systematic review of the literature and develop best-practice guidance related to SARS-CoV-2 Ag testing. This guideline is the third in a series of rapid, frequently updated COVID-19 diagnostic guidelines developed by IDSA. IDSA’s goal was to develop evidence-based recommendations or suggestions that assist clinicians, clinical laboratories, patients, public health authorities, administrators, and policymakers in decisions related to the optimal use of SARS-CoV-2 Ag tests in both medical and nonmedical settings. A multidisciplinary panel of infectious diseases clinicians, clinical microbiologists, and experts in systematic literature review identified and prioritized clinical questions related to the use of SARS-CoV-2 Ag tests. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make testing recommendations. The panel agreed on 5 diagnostic recommendations. These recommendations address Ag testing in symptomatic and asymptomatic individuals as well as assess single versus repeat testing strategies. Data on the clinical performance of US Food and Drug Administration SARS-CoV-2 Ag tests with Emergency Use Authorization are mostly limited to single, one-time testing versus standard nucleic acid amplification testing (NAAT) as the reference standard. Rapid Ag tests have high specificity and low to modest sensitivity compared with reference NAAT methods. Antigen test sensitivity is heavily dependent on viral load, with differences observed between symptomatic compared with asymptomatic individuals and the time of testing post-onset of symptoms. Based on these observations, rapid reverse transcriptase–polymerase chain reaction (RT-PCR) or laboratory-based NAAT remain the diagnostic methods of choice for diagnosing SARS-CoV-2 infection. However, when molecular testing is not readily available or is logistically infeasible, Ag testing can help identify some individuals with SARS-CoV-2 infection. The overall quality of available evidence supporting use of Ag testing was graded as very low to moderate.
Circulating progenitor cells are associated with plaque progression and long-term outcomes in heart transplant patients
Toya, Takumi , Corban, Michel , Ahmad, Ali , Loeffler, Darrell , Morse, David , Lerman, Lilach O. , Kushwaha, Sudhir S. , Lerman, Amir , Ozcan, Ilke, Toya, Takumi , Corban, Michel T , Ahmad, Ali , Loeffler, Darrell , Morse, David , Lerman, Lilach O , Lerman, Amir , Ӧzcan, Ilke

Mayo Clinic

Cardiovascular Research | June 14, 2021 | Volume: 118 | Issue: 7 | Pages: 1703-1712

10.1093/cvr/cvab203 | PMID 34132771 Get It

Abstract Aims Circulating progenitor cells (CPCs) play a role in vascular repair and plaque stability, while osteocalcin (OC) expressing CPCs have been linked to unstable plaque and adverse cardiovascular outcomes. However, their role in cardiac allograft vasculopathy (CAV) has not been elucidated. This cohort study aimed to investigate the contribution of CPCs on CAV progression and cardiovascular events after heart transplantation. Methods and results A total of 80 heart transplant patients (mean age 55 ± 14 years, 72% male) undergoing annual intravascular ultrasound (IVUS) had fresh CPCs marked by CD34, CD133, and OC counted in peripheral blood using flow cytometry, on the same day as baseline IVUS. CAV progression was assessed by IVUS as the change (Δ) in plaque volume divided by segment length (PV/SL), adjusted for the time between IVUS measurements [median 3.0, interquartile range (2.8–3.1) years] and was defined as ΔPV/SL that is above the median ΔPV/SL of study population. Major adverse cardiac events (MACEs) were defined as any incident of revascularization, myocardial infarction, heart failure admission, re-transplantation, stroke, and death. Patients with higher CD34+CD133+ CPCs had a decreased risk of CAV progression [odds ratio 0.58, 95% confidence interval (CI) (0.37–0.92), P = 0.01] and MACE [hazard ratio (HR) 0.79, 95% CI (0.66–0.99), P = 0.05] during a median (interquartile range) follow-up of 8.0 years (7.2–8.3). Contrarily, higher OC+ cell counts were associated with an increased risk of MACE [HR 1.26, 95% CI (1.03–1.57), P = 0.02]. Conclusions Lower levels of CD34+CD133+ CPCs are associated with plaque progression and adverse long-term outcomes in patients who underwent allograft heart transplantation. In contrast, higher circulating OC+ levels are associated with adverse long-term outcomes. Thus, CPCs might play a role in amelioration of transplant vasculopathy, while OC expression by these cells might play a role in progression.
Early role for a Na + ,K + -ATPase ( ATP1A3 ) in brain development
Smith, Richard S. , Akula, Shyam K. , Neil, Jennifer E., Wang, Yidi , Hill, Robert , Goldman, Melissa , Mullally, Christopher D. , Reed, Nora , Bello‐Espinosa, Luis , Flores‐Sarnat, Laura , Monteiro, Fabíola Paoli , Casella, Erasmo Barbante , Barkovich, A. James , Gonzalez–Heydrich, Joseph , Florio, Marta , Akula, Shyam K , Wang, Yidi , Bello-Espinosa, Luis , Erasmo, Casella B , Vairo, Filippo , Barkovich, A James , Gonzalez-Heydrich, Joseph , Walsh, Christopher A , Hill, R. Sean, Vairo, Filippo Pinto e , Morava, Éva , Brownstein, Catherine A. , McCarroll, Steven A. , Walsh, Christopher A.

Mayo Clinic

Proceedings of the National Academy of Sciences | June 14, 2021 | Volume: 118 | Issue: 25 | Pages: No page available

10.1073/pnas.2023333118 | PMID 34161264 Get It

Significance By evaluating children with a malformed cerebral cortex, we identified an ATPase pump (ATP1A3) with an early role in brain development. The ATP1A3 pump maintains the physiological concentration of sodium and potassium ions in cells, a process critical for osmotic equilibrium and membrane potential across several developing cell populations. We employed single-cell sequencing approaches to identify key enrichments for ATP1A3 expression during human cortex development. Unravelling this early cell-type–specific pathophysiology in the developing brain offers a potential basis for the treatment of ATP1A3 -related diseases affecting prenatal and early childhood development.